Ralph Schneider

Ralph Schneider

Auto-generated profile, based on publicly available information

Ralph Schneider

Kliniken Essen-Mitte

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2011 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
RSRalph Schneider
Ralph Schneider
ESEmily P. Slater
Emily P. Slater
MSMercede Sina
Mercede Sina
NHNils Habbe
Nils Habbe
VFVolker Fendrich
Volker Fendrich
DBDetlef K. Bartsch
Detlef K. Bartsch

28 December 2011 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
RSRalph Schneider
Ralph Schneider
ESEmily P. Slater
Emily P. Slater
EKElias Karakas
Elias Karakas
DBDetlef K. Bartsch
Detlef K. Bartsch
KSKatja Schlosser
Katja Schlosser


9 April 2011 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
RSRalph Schneider
Ralph Schneider
JWJens Waldmann
Jens Waldmann
ARAnnette Ramaswamy
Annette Ramaswamy
EFEmilio Domínguez Fernández
Emilio Domínguez Fernández
DBDetlef K. Bartsch
Detlef K. Bartsch
KSKatja Schlosser
Katja Schlosser

1 March 2011 in Pancreas
Verified
Journal Article
Closed access
RSRalph Schneider
Ralph Schneider
JWJens Waldmann
Jens Waldmann
ZSZaher Swaid
Zaher Swaid
ARAnnette Ramaswamy
Annette Ramaswamy
VFVolker Fendrich
Volker Fendrich
KSKatja Schlosser
Katja Schlosser
Objective: Pancreatic endocrine tumors (PETs) are characterized by the presence of hormone syndromes. Reports focusing on calcitonin-secreting PET (CTsPETs) are very rare. This study aimed to define a CTsPET-associated syndrome in regard to chemical, anatomical, and developmental aspects. Methods: A computerized MEDLINE search was conducted under the search items: "pancreatic endocrine tumor," "calcitonin," "neuroendocrine pancreatic tumor," and "pancreas." Results of clinical, histopathological, immunohistochemical, and biochemical assessments of all patients identified with CTsPET were registered and statistically analyzed. Results: Thirty-seven patients with CTsPET were identified. Mean serum calcitonin was elevated to the 89.2-fold of the upper reference value. Main symptoms were watery diarrhea (51.4%) and abdominal pain (35.1%). Most patients (59.5%) presented with metastatic spread at the time of diagnosis. Of all patients, 66.7% were alive after a mean follow-up of 28.9 months. Survival was higher in patients who underwent more aggressive surgical therapies independent from tumor sizes and in those with no metastases at the time of diagnosis. Conclusions: High calcitonin levels should always raise suspicion of medullary thyroid carcinomas. However, when thyroid examination remains without pathological findings, a CTsPET should be excluded. An aggressive surgical approach even in cases with large primary tumor sizes may lead to a longer survival.

1 February 2011 in Neoplasia
Verified
Journal Article
Open access
VFVolker Fendrich
Volker Fendrich
RSRalph Schneider
Ralph Schneider
AMAnirban Maitra
Anirban Maitra
Ilse JacobsenIlse Jacobsen
Ilse Jacobsen
TOThomas Opfermann
Thomas Opfermann
DBDetlef K. Bartsch
Detlef K. Bartsch
Pancreatic cancer is among the most dismal of human malignancies. The 5-year survival rate is lower than 5%. The identification of precursor lesions would be the main step to improve this fatal outcome. One precursor lesions are called pancreatic intraepithelial neoplasia (PanIN) and are graduated in grade 1 to 3, whereas grade 3 is classified as carcinoma in situ. Currently, no reliable, noninvasive imaging technique (e.g., ultrasound, computed tomography, magnet resonance imaging) exists to verify PanINs. Recently, a transgenic mouse model of pancreatic cancer was established in which the tumor progression of human pancreatic carcinoma is reproduced. These so-called Pdx-1-Cre; LSL-KrasG12D/+; LSL-Trp53R172H/+mice develop PanINs, which transform to invasive growing pancreatic carcinoma. The pancreata of mice of different ages were immunohistochemically stained using α-GLUT-2 antibodies. Furthermore, mice underwent positron emission tomography (PET)-computed tomography (CT) with (18)F-fluorodeoxyglucose (FDG) to evaluate early detection of PanIN lesions. An expression of GLUT-2 in murine PanINs was found in PanINs of grade 1B and higher. This finding is associated with an elevated glucose metabolism, leading to the detection of precursor lesions of pancreatic cancer in the FDG PET-CT scan. In addition, immunohistochemical staining of GLUT-2 was detectable in 45 (75%) of 60 human PanINs, whereas PanINs of grade 1B and higher showed a very extensive expression. In conclusion, we demonstrate for the first time that an elevated glucose metabolism occurs already in precursor lesions of murine and human pancreatic carcinoma. These findings are the basis for the detection of precursor lesions by PET-CT, thereby helping improving the prognosis of this devastating disease.